Citadel Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Citadel Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,568	Closed	-$103K	–	14744
2021 Q1	$103K	Buy	+1,568	New	+$119K	﹤0.01%	12453
2020 Q4	–	Sell	-744	Closed	-$44K	–	11738
2020 Q3	$44K	Buy	744 +403	+118%	+$36K	﹤0.01%	9651
2020 Q2	$44K	Buy	+341	New	+$30.1K	﹤0.01%	9360
2019 Q4	–	Sell	-131	Closed	-$16K	–	9985
2019 Q3	$16K	Sell	131 -83	-39%	-$16.7K	﹤0.01%	8990
2019 Q2	$64K	Buy	214 +130	+155%	+$54.2K	﹤0.01%	8663
2019 Q1	$38K	Sell	84 -387	-82%	-$169K	﹤0.01%	8924
2018 Q4	$216K	Buy	+471	New	+$292K	﹤0.01%	7752
2018 Q3	–	Sell	-88	Closed	-$52K	–	9873
2018 Q2	$52K	Sell	88 -61	-41%	-$39.8K	﹤0.01%	8432
2018 Q1	$97K	Buy	+149	New	+$112K	﹤0.01%	7725
2016 Q4	–	Sell	-59	Closed	-$25K	–	8040
2016 Q3	$25K	Buy	+59	New	+$26.4K	﹤0.01%	6996

Other funds holding HTGM

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's HTGM Position: Q2 2021 in Review

Citadel Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2021, closing a stake of 1,568 shares — an estimated $103K sold.

Citadel Advisors first reported a position in HTGM in Q3 2016 and held it in 10 quarters. The position peaked at $216K in Q4 2018. 24 funds tracked by Wall St. Rank hold HTGM as of Q2 2021.

Citadel Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Citadel Advisors sold 1,568 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2021, an estimated $103K.
Citadel Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2016 and held it in 10 quarters.
Citadel Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $216K in Q4 2018.
24 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2021.

Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.